NCT03890289 2024-11-21
GAUDEALIS
Fondazione Italiana Linfomi - ETS
Phase 2 Terminated
Clinical Trials
8 trialsNCT04699461 2023-10-23
LOTIS-6
ADC Therapeutics S.A.
Phase 2 Terminated
NCT01620216 2021-11-04
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT01796470 2020-06-02
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
Gilead Sciences
Phase 2 Terminated
NCT02258529 2019-05-14
Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma
Gilead Sciences
Phase 2 Terminated
NCT02044822 2018-11-19
Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion
Gilead Sciences
Phase 2 Terminated
NCT01203930 2018-11-16
A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL
Gilead Sciences
Phase 2 Terminated
NCT02439138 2017-01-11
Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia
Dana-Farber Cancer Institute
Phase 2 Terminated